DELANEY MARK E sold $376K of DGX

DELANEY MARK E (SVP & Chief Commercial Officer) sold 1,600 shares of QUEST DIAGNOSTICS INC (DGX) at $235.18 ($0.38M total) on 2026-07-28 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · DELANEY MARK E
Published Jul 29, 2026, 9:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 29, 2026, 9:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$DGX
Neutral
high confidence
Mentioned
$DGX
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DGXNeutralLow
01

Why it matters

Because the sale is open-market and pre-arranged under a 10b5-1 plan, it is generally not a strong standalone catalyst for trading decisions.

02

Market read

Traders may note the filing for completeness, but it does not introduce new fundamental information.

03

What to watch

The transaction size and the fact it is a planned 10b5-1 sale make it less informative than unscheduled sales or purchases tied to specific events.

Relevance 3/10Novelty 2/10Timing: as of the 2026-07-29 after SEC filing timestamp

Background

The article is an SEC Form 4 insider transaction disclosure for Quest Diagnostics (DGX).

Company-level read

Ticker impact

$DGXNeutralHigh confidence
Context

Quest Diagnostics Form 4 shows SVP Mark E Delaney sold 1,600 shares on 2026-07-28 under a pre-arranged 10b5-1 plan.

Expected impact

Likely minimal impact on DGX price; any effect is typically short-lived and outweighed by broader fundamentals.

Evidence & confidence

The filing is a Form 4 insider transaction, explicitly pre-arranged under Rule 10b5-1, and provides no new company-specific operational or financial information.

Market effects

No direct read-across to diagnostics sector fundamentals from a single routine insider sale.

None.

None.

Counterpoint

Insider sales can sometimes reflect private risk perceptions, but the 10b5-1 pre-arrangement reduces interpretability.

Key entities

  • Quest Diagnostics

    DGX, the company whose insider transaction is disclosed.

  • Delaney Mark E

    SVP and Chief Commercial Officer who sold shares.

  • Rule 10b5-1 plan

    Pre-arranged plan that typically limits the informational value of the sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$DGXLow

Quest Diagnostics Pays $13 Million to Settle Kickback Allegations Involving New York Giants Tickets

Quest Diagnostics will pay $13M to settle allegations of illegal kickbacks, including New York Giants tickets, to healthcare providers. The U.S. Attorney's Office claims the company violated the Anti-Kickback Statute from 2013 to 2022, offering perks in exchange for business referrals. Quest denies wrongdoing but agreed to a settlement and a 5-year compliance agreement.

$DGXLow

Quest Diagnostics pays more than $13M to settle alleged kickback scheme, federal prosecutors say

Quest Diagnostics agreed to pay $13M to settle allegations of a kickback scheme involving gifts to hospital executives, including New York Giants game tickets, according to federal prosecutors. The scheme allegedly lasted from 2013 to 2022, with Quest billing government-funded medical plans. The company will also face five years of auditing. Quest reported $11B in 2025 revenue, up 7%.

$DGXLow

Quest Diagnostics pays $13M to settle kickback allegations involving NY Giants tickets

Quest Diagnostics agreed to pay $13M to settle allegations of providing illegal kickbacks, including NY Giants tickets, to healthcare providers for referrals, according to the U.S. Attorney’s Office of New Jersey. The settlement resolves claims of violating the Anti-Kickback Statute and submitting false claims to Medicare and Medicaid. Quest denies wrongdoing but agreed to the settlement to resolve the matter.

$DGXLow

Quest Diagnostics pays more than $13 million to settle allegations of illegal kickbacks involving Giants tickets, VIP events

Quest Diagnostics Inc. paid $13,014,576 plus interest to settle federal allegations of illegal kickbacks involving free New York Giants tickets and VIP events to induce patient referrals. The company violated the Anti-Kickback Statute and submitted false claims to Medicare and Medicaid programs, according to the U.S. Attorney’s Office. Quest also entered a five-year Corporate Integrity Agreement with HHS-OIG. Whistleblowers will receive nearly $2.5 million.

$LHMed

Labcorp, Quest urge RESULTS Act passage as lab payment cuts loom

Labcorp and Quest Diagnostics warn of revenue impacts from upcoming Medicare and Medicaid reimbursement cuts starting in 2027. Labcorp expects a $125 million hit, while Quest estimates a 1% revenue reduction in 2026. Both companies advocate for the passage of the RESULTS Act to reform the payment rate-setting process, citing concerns over patient access and lab viability.